Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Abraxis Acquires Drug From Scripps
August 27, 2007
| A version of this story appeared in
Volume 85, Issue 35
Abraxis BioScience has licensed a potential cancer drug from Scripps Research Institute for an undisclosed sum. Abraxis will evaluate the therapeutic potential of the epothilone agent in combination with its "nab" technology, which uses human protein albumin to carry an anticancer drug to its target. The company claims the delivery method allows high concentrations of the drug to reach tumors while reducing side effects associated with solvent-based delivery systems. Abraxis also gains the rights to 11 other potential drug candidates, one of which could be chosen for clinical development.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter